.
.
.
.
Coronavirus

Novavax completes patient enrollment in US trials for COVID-19 vaccine

Published: Updated:

Drug developer Novavax Inc said on Monday it has completed patient enrollment in the late-stage study of its COVID-19 vaccine in the United States and Mexico.

The company said last month its vaccine was 89.3 percent effective in preventing COVID-19 in a trial conducted in the United Kingdom and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK.

For more coronavirus news, visit our dedicated page.

Novavax said it had enrolled 30,000 volunteers across the United States and Mexico.

In the late-stage trial, the company said 20 percent of participants were Latinx, 13 percent were African American, and 13 percent were 65 and older.

Read more:

Novavax COVID vaccine highly effective, but not against South Africa variant

Explainer: Coronavirus shots might be tweaked if variants get worse

Coronavirus: Fresh data show toll S. African virus variant takes on vaccine efficacy